ReviewOncology letters2026
Roles of minimally invasive techniques in the management of epithelial ovarian cancer (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is a leading cause of mortality among gynecological malignancies, predominantly due to late-stage diagnoses and complex management challenges. Traditional treatment strategies, primarily centered on extensive cytoreductive surgery and platinum-based chemotherapy, have seen notable improvements through the integration of laparoscopy and robotic-assisted procedures. The safety and efficacy of minimally invasive techniques (MITs) have been demonstrated in early-stage EOC, although their applicability in advanced stages requires further investigation. Additionally, molecular-based and immunotherapies, including poly(ADP-ribose) polymerase inhibitors, angiogenesis inhibitors and RNA-based treatments, offer promising adjuncts to MITs by targeting cancer-specific pathways with precision. Despite these innovations, patient selection, surgical expertise and adherence to oncological safety standards remain key factors in determining the efficacy and safety of MITs in EOC management. Future directions emphasize the need for standardized protocols, enhanced imaging techniques and real-time molecular monitoring, which aim to transition EOC management toward a minimally invasive, patient-centered approach. The present review discussed the advancements in MITs and their role in the management of EOC, with a focus on their impact on surgical outcomes, survival rates and patient quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.